CTNM - Contineum Therapeutics, Inc. Class A Common Stock

Price Target Consensus

21.33

Consensus Target

28

High Target

19

Median Target

17

Low Target

Price Target News & Updates

Date	Analyst	Company	Price Target	News Title
2026-09-30	Paul Matteis	Stifel Nicolaus	$28	Stifel Reiterates Buy Rating on Contineum Therapeutics (CTNM)
2026-09-27	Sean Laaman	Morgan Stanley	$17	Contineum price target lowered to $17 from $18 at Morgan Stanley
2026-09-15	N/A	Robert W. Baird	$19	Contineum price target lowered to $19 from $20 at Baird
2026-05-14	N/A	Morgan Stanley	$16	Contineum price target raised to $16 from $14 at Morgan Stanley
2026-01-08	N/A	Morgan Stanley	$14	Contineum downgraded to Equal Weight from Overweight at Morgan Stanley
2025-11-24	N/A	Robert W. Baird	$14	Contineum price target lowered to $14 from $16 at Baird
2025-11-21	Brian Abrahams	RBC Capital	$22	Contineum price target lowered to $22 from $25 at RBC Capital
2025-09-25	N/A	Leerink Partners	$20	Contineum initiated with an Outperform at Leerink
2025-03-07	N/A	Robert W. Baird	$16	Contineum price target lowered to $16 from $32 at Baird
2024-10-21	Joel Beatty	Robert W. Baird	$32	Baird Starts Contineum Therapeutics (CTNM) at Outperform